Acadia Pharmaceuticals (NASDAQ: ACAD) raises 2026 guidance on Q2 sales growth
Rhea-AI Filing Summary
Acadia Pharmaceuticals reported GAAP total revenues of $308 million for the quarter ended June 30, 2026, up 16% from $265 million a year earlier and 17% versus non-GAAP adjusted revenues. NUPLAZID net sales were $183 million, up 9% year-over-year and 10% on a non-GAAP adjusted basis, while DAYBUE net sales reached $125 million, up 30%. Quarterly net income was $32 million, or $0.18 per diluted share, and cash, cash equivalents and investment securities totaled $956 million.
The company raised its 2026 total revenue guidance to $1.24–$1.30 billion, increased DAYBUE sales guidance to $480–$510 million, and lowered expected R&D expenses to $355–$380 million. Acadia highlighted progress for remlifanserin in Alzheimer’s disease psychosis, including FDA Fast Track designation and ongoing RADIANT Phase 2/3 work, and noted a CHMP positive opinion recommending EU marketing authorization for DAYBU in Rett syndrome.
Positive
- GAAP total revenues grew 16% year-over-year to $308 million, with net income increasing to $32 million and diluted EPS of $0.18.
- Management raised 2026 total revenue guidance to $1.24–$1.30 billion, lifted DAYBUE sales guidance to $480–$510 million, and reduced R&D expense guidance to $355–$380 million.
- Remlifanserin received FDA Fast Track designation, and CHMP issued a positive opinion recommending EU marketing authorization for DAYBU in Rett syndrome.
Negative
- None.
Filing Explained
Acadia completed Phase 2 enrollment for remlifanserin, began Phase 3 screening and enrollment, and expects Phase 2 topline results in September to October 2026; the program has advanced into its next clinical stage, while its Phase 2 outcome remains unresolved.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 total revenues: $308 million
Q2 2026 NUPLAZID net sales: $183 million
Q2 2026 DAYBUE net sales: $125 million
+5 more
8 metrics
Q2 2026 total revenues
$308 million
GAAP total revenues for the quarter ended June 30, 2026, up 16% from $265 million in Q2 2025
Q2 2026 NUPLAZID net sales
$183 million
GAAP net product sales, up 9% year-over-year and 10% on a non-GAAP adjusted basis
Q2 2026 DAYBUE net sales
$125 million
Net product sales for the second quarter of 2026, up 30% from $96 million in Q2 2025
Q2 2026 net income
$32 million
Net income for the second quarter of 2026, compared to $27 million in the prior-year quarter
Cash and investments
$956 million
Cash, cash equivalents and investment securities as of June 30, 2026
2026 total revenue guidance
$1.24–$1.30 billion
Revised full-year 2026 GAAP total revenue outlook, increased from $1.22–$1.28 billion
2026 DAYBUE sales guidance
$480–$510 million
Full-year 2026 global DAYBUE net product sales guidance, raised from $460–$490 million
2026 R&D expense guidance
$355–$380 million
Full-year 2026 R&D expense range, lowered from prior guidance of $385–$410 million
Key Terms
Fast Track designation, non-GAAP adjusted total revenues, Phase 2 portion of the RADIANT program, positive opinion recommending marketing authorization, +1 more
5 terms
Fast Track designation regulatory
"Received FDA Fast Track designation for remlifanserin for the treatment of hallucinations"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
non-GAAP adjusted total revenues financial
"up 17% as compared to non-GAAP adjusted total revenues of $262 million"
Phase 2 portion of the RADIANT program medical
"Completed enrollment in the Phase 2 portion of the RADIANT program evaluating remlifanserin"
positive opinion recommending marketing authorization regulatory
"CHMP of the EMA adopted a positive opinion recommending marketing authorization for DAYBU"
Rett syndrome medical
"for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients"
A rare genetic disorder that disrupts normal brain development in young children, most commonly girls, leading to slowed growth, loss of purposeful hand use, repetitive hand movements, motor problems, speech loss, and cognitive and breathing irregularities. Investors watch it because its severity and few treatment options create clear medical need and potential markets for therapies; think of it as a broken traffic signal in the brain that, if fixed, could restore many downstream functions.
Earnings Snapshot
GAAP total revenues: $308 million · Guidance included
second quarter 2026
GAAP total revenues
$308 million
Up 16% from GAAP total revenues of $265 million in Q2 2025 and 17% versus non-GAAP adjusted $262 million.
NUPLAZID net sales
$183 million
Up 9% from GAAP $168 million and 10% versus non-GAAP adjusted $166 million in Q2 2025.
DAYBUE net sales
$125 million
Increased 30% from $96 million in the second quarter of 2025.
Net income
$32 million
Compared to net income of $27 million in the same period in 2025.
Guidance
For 2026, Acadia guides to total revenues of $1.24–$1.30 billion, NUPLAZID net sales of $760–$790 million, DAYBUE net sales of $480–$510 million, R&D expenses of $355–$380 million, and SG&A expenses of $660–$700 million.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Acadia (ACAD) perform financially in Q2 2026?
Acadia reported GAAP total revenues of $308 million in Q2 2026, up 16% from $265 million a year earlier. Net income was $32 million, or $0.18 per diluted share, reflecting continued profitability alongside growing product sales.
What were DAYBUE and NUPLAZID sales for Acadia (ACAD) in Q2 2026?
In Q2 2026, Acadia generated $125 million in DAYBUE net sales, up 30% year-over-year, and $183 million in NUPLAZID GAAP net sales, up 9% year-over-year and 10% on a non-GAAP adjusted basis, driven by strong demand and commercial execution.
What 2026 financial guidance did Acadia (ACAD) provide?
Acadia now expects 2026 total revenues of $1.24–$1.30 billion. Guidance includes NUPLAZID net sales of $760–$790 million, DAYBUE global net sales of $480–$510 million, R&D expenses of $355–$380 million, and SG&A expenses of $660–$700 million.
What is the status of Acadia (ACAD)'s remlifanserin program?
Acadia completed enrollment in the Phase 2 portion of the RADIANT program for remlifanserin in Alzheimer’s disease psychosis and initiated Phase 3 screening. Topline Phase 2 results are anticipated in September to October 2026, and the FDA granted Fast Track designation.
What regulatory milestones did Acadia (ACAD) report for DAYBUE?
The CHMP of the EMA adopted a positive opinion recommending marketing authorization for DAYBU (trofinetide) to treat Rett syndrome in patients aged five and older. If approved by the European Commission, DAYBU would be the first authorized Rett syndrome treatment in the EU.
What is Acadia (ACAD)'s cash position after Q2 2026?
At June 30, 2026, Acadia held $956 million in cash, cash equivalents and investment securities, up from $820 million at December 31, 2025, providing substantial financial resources to support commercialization and ongoing clinical development programs.